# A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

> **NCT01630733** · PHASE3 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 664 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Custirsen
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01630733
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-24
- **Primary completion:** 2016-11-17
- **Final completion:** 2016-11-17
- **Target enrollment:** 664 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630733, "A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01630733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*